Neuroepithelial, Perineurial, and Schwann Cell Neoplasm — knowledge graph · CancerIndex

Knowledge graph · Cancer

Neuroepithelial, Perineurial, and Schwann Cell Neoplasm

cancer family

Identifier: CI-CAN-00000039
Entity page: /cancer/neuroepithelial-perineurial-and-schwann-cell-neoplasm ↗
Edges: 3,810

Neighbours: 15 genes18 drugs10 trials
Drawn: 43 of 43 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm approved for …APPROVED_FORderived15 of 20show all (up to 200)
← approved for	Dordavipronesmall molecule FDA (US) · approved · 2025-08-06 · MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 …	—	approved	Diffuse Midline Glioma	1	Regulatory	openfda	graph →

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

NF1 Mutation Selumetinib13 active / 17 trials
Curatedlevel Asensitivity· support 3civicObservedNF1 altered in 14% (142 / 1,004 cases, largest of 11 cohorts)no approval record in this cancercontext: Plexiform Neurofibroma, Childhood Low Grade Glioma
H3-3A K28M DordaviproneFDA US 2025-08-063 active / 12 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for H3-3A in this cancerRegulatoryapproved for Diffuse Midline Gliomacontext: Glioma, Diffuse Midline Glioma, H3 K27-Altered
IDH1 Mutation Vorasidenib6 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 34% (339 / 1,004 cases, largest of 13 cohorts)no approval record in this cancercontext: Glioma
IDH1 R132C Vorasidenib6 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 34% (339 / 1,004 cases, largest of 13 cohorts)no approval record in this cancercontext: Low Grade Glioma
IDH1 R132G Vorasidenib6 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 34% (339 / 1,004 cases, largest of 13 cohorts)no approval record in this cancercontext: Low Grade Glioma
IDH1 R132H Vorasidenib6 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 34% (339 / 1,004 cases, largest of 13 cohorts)no approval record in this cancercontext: Low Grade Glioma
IDH1 R132L Vorasidenib6 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 34% (339 / 1,004 cases, largest of 13 cohorts)no approval record in this cancercontext: Low Grade Glioma
IDH1 R132S Vorasidenib6 active / 9 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 34% (339 / 1,004 cases, largest of 13 cohorts)no approval record in this cancercontext: Low Grade Glioma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Neuroepithelial, Perineurial, and Schwann Cell Neoplasm altered in cohorts of …ALTERED_INderived15 of 432show all (up to 200)
← altered in cohorts of	NF2 31 / 40 cases (78 %) · ssm · schw_ctf_synodos_2025	—	—	Schwannoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ATRNL1 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MYOF 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SEC23IP 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	BAG3 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CACUL1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	EIF3A 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	INPP5F 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MCMBP 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	PRLHR 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SORBS1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTA2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CTBP2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CYP26C1 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	DENND10 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →

Neuroepithelial, Perineurial, and Schwann Cell Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 228show all (up to 200)
→ investigated in trials for	Temozolomidesmall molecule 377 trials (117 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	377	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 148 trials (24 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	148	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 53 trials (23 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	53	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 47 trials (24 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Lomustinesmall molecule 44 trials (13 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 43 trials (12 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 36 trials (17 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 31 trials (6 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 29 trials (9 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 23 trials (4 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 22 trials (8 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 20 trials (3 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 19 trials (5 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 18 trials (8 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 18 trials (1 active) · roll-up of the cancer and its descendants	—	—	Neuroepithelial, Perineurial, and Schwann Cell Neoplasm	18	Observed	clinicaltrials	graph →

Neuroepithelial, Perineurial, and Schwann Cell Neoplasm studied in …STUDIED_INderived10 of 3,130show all (up to 200)
→ studied in	NCT00314119completed Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 · condition mapped ONTOLOGY_EXACT · 3,130 trials mapped (1,040 active)	—	—	Neurofibroma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01109394recruiting Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies · condition mapped ONTOLOGY_EXACT · 3,130 trials mapped (1,040 active)	—	—	Retinoblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01362803Phase 1/Phase 2 · active not recruiting AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors · condition mapped ALIAS · 3,130 trials mapped (1,040 active)	—	—	Plexiform Neurofibroma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01445288completed Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors · condition mapped ONTOLOGY_EXACT · 3,130 trials mapped (1,040 active)	—	—	Diffuse Intrinsic Pontine Glioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303467Phase 1 · recruiting A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM · condition mapped CURATED_BROADER · 3,130 trials mapped (1,040 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05432804Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · condition mapped CURATED_BROADER · 3,130 trials mapped (1,040 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT07145112Phase 1 · recruiting Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma · condition mapped CURATED_BROADER · 3,130 trials mapped (1,040 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07326566Phase 2 · recruiting Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII · condition mapped CURATED_BROADER · 3,130 trials mapped (1,040 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07416188Phase 1/Phase 2 · recruiting Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma · condition mapped CURATED_BROADER · 3,130 trials mapped (1,040 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07844460enrolling by invitation 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features · condition mapped ONTOLOGY_EXACT · 3,130 trials mapped (1,040 active)	—	—	Vestibular Schwannoma	1	Observed	clinicaltrials	graph →